Research
Mopping Up Leftover Tumors After Dual Immunotherapy Didn’t Help Lung Cancer Patients Live Longer
The phase 3 LONESTAR trial tested a widely assumed strategy — radiate or resect what remains after checkpoint blockade — and found no survival benefit, not even in the oligometastatic patients it was supposed to help most.